特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

20Sプロテアソーム:パイプライン製品の分析

20s Proteasome - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 363576
出版日 ページ情報 英文 76 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
20Sプロテアソーム:パイプライン製品の分析 20s Proteasome - Pipeline Review, H1 2020
出版日: 2020年05月30日 ページ情報: 英文 76 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、20Sプロテアソーム薬剤の開発状況関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

20Sプロテアソームの概要

治療薬の開発

  • 20Sプロテアソーム:開発中の製品 - 開発段階別
  • 20Sプロテアソーム:開発中の製品 - 治療範囲別
  • 20Sプロテアソーム:開発中の製品 - 適応症別
  • 20Sプロテアソーム:開発中の製品 - 企業別
  • 20Sプロテアソーム:開発中の製品 - 大学・研究機関別

20Sプロテアソーム:治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

20Sプロテアソームの治療薬開発に従事している企業

  • Amgen Inc.
  • Celgene Corp

20Sプロテアソーム:薬剤プロファイル

20Sプロテアソーム:休止中のプロジェクト

20Sプロテアソーム:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Amgen Inc, H1 2020
  • Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Pipeline by Centrax International Inc, H1 2020
  • Pipeline by Hibiskus Biopharma Inc, H1 2020
  • Pipeline by HuniLife Biotechnology Inc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
目次
Product Code: GMDHC2418TDB

Summary:

According to the recently published report '20s Proteasome - Pipeline Review, H1 2020'; 20s Proteasome pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides.

The report '20s Proteasome - Pipeline Review, H1 2020' outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Metabolic Disorders which include indications Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Multiple Myeloma (Kahler Disease), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Amyloidosis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Leukemia, Lung Transplant Rejection, Malignant Glioma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Renal Cell Carcinoma, Small-Cell Lung Cancer and Tuberculosis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for 20s Proteasome
  • The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects
  • The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 20s Proteasome
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • 20s Proteasome - Overview
    • 20s Proteasome - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • 20s Proteasome - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • 20s Proteasome - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Bristol-Myers Squibb Co
    • Centrax International Inc
    • Hibiskus Biopharma Inc
    • HuniLife Biotechnology Inc
  • 20s Proteasome - Drug Profiles
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CX-13608 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HuL-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • 20s Proteasome - Dormant Products
  • 20s Proteasome - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer